Breaking News Instant updates and real-time market news.

IPSEY

Ipsen

, EXEL

Exelixis

$12.95

-0.23 (-1.75%)

05:26
10/10/16
10/10
05:26
10/10/16
05:26

Ipsen, Exelixis announces results from Phase 2 CABOSUN phase 2 trial

Ipsen (IPSEY) and its partner Exelixis (EXEL) announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma, or RCC, with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium, or IMDC. In CABOSUN, with a median follow-up of 20.8 months, cabozantinib demonstrated a clinically meaningful and statistically significant 31% reduction in the rate of disease progression or death. The median progression-free survival, or PFS, for cabozantinib was 8.2 months versus 5.6 months for sunitinib, corresponding to a 2.6 months improvement favoring cabozantinib over sunitinib. PFS benefits were independent of IMDC risk group and presence or absence of bone metastases at baseline. The results for sunitinib were in line with a previously published retrospective analysis of 1,174 intermediate- and poor-risk RCC patients from the IMDC database, which documented a median PFS of 5.6 months with a first-line targeted therapy, mainly sunitinib, in this patient population.

IPSEY

Ipsen

EXEL

Exelixis

$12.95

-0.23 (-1.75%)

  • 10

    Oct

  • 10

    Oct

IPSEY Ipsen

03/08/16
LEHM
03/08/16
DOWNGRADE
LEHM
Equal Weight
Ipsen downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Mark Purcell downgraded Ipsen to Equal Weight with a EUR 53 price target.
04/26/16
JEFF
04/26/16
UPGRADE
JEFF
Buy
Ipsen upgraded to Buy from Hold at Jefferies
05/09/16
MSCO
05/09/16
UPGRADE
MSCO
Overweight
Ipsen upgraded to Overweight from Equal Weight at Morgan Stanley
07/07/16
JPMS
07/07/16
DOWNGRADE
JPMS
Neutral
Ipsen downgraded to Neutral from Overweight at JPMorgan
EXEL Exelixis
$12.95

-0.23 (-1.75%)

08/04/16
STFL
08/04/16
NO CHANGE
STFL
Exelixis price target raised to $12 from $10 at Stifel
Stifel analyst Stephen Willey raised his price target on Exelixis after the company reported significantly better than expected Cabometyx and residual/off-label Cometriq sales into the newly launched indication of refractory renal cell carcinom. Willey expects the results to improve investors' confidence towards the company's growth outlook, and he says that anticipation of front-line CABOSUN results places a near-term floor on the stock. The analyst keeps a Buy rating on the shares.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Exelixis selloff overdone, says Leerink
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.